Germany's ERBA Diagnostics grabs Lumora for molecular Dx tech

ERBA Diagnostics Mannheim CEO Suresh Vazirani

German in vitro diagnostics company ERBA Diagnostics Mannheim is snatching up Lumora to get its hands on the company's molecular diagnostic products. Neither side is revealing financial terms, but the deal will allow ERBA Diagnostics Mannheim to market Lumora's tests for hospital-acquired infections, HIV, respiratory disease and other neglected diseases to a larger global market. Lumora also brings ongoing commercial partnerships to the table that will continue after the deal is complete, allowing ERBA Diagnostics Mannheim to further expand its global footprint. "Lumora has a strong portfolio of molecular technologies which will help us develop molecular testing for emerging country specific diseases such as HIV and dengue. We look forward to working with the talented team at Lumora to further integrate our businesses for the benefit of our customers," ERBA Diagnostics Mannheim CEO Suresh Vazirani said in a statement. Statement

Suggested Articles

Medtronic's new data shows its catheter-based ablation procedure, aimed at the kidneys, can help lower high blood pressure where drugs have failed.

At the two-year mark, the data show TAVR and open surgery patients are equivalent when it comes to risks of stroke, hospitalization and death.

Abbott launched a rapid coronavirus test able to deliver positive results in as little as five minutes from a tabletop box the size of a toaster.